Clinical Trials Logo

Gastric Cancer Stage IV clinical trials

View clinical trials related to Gastric Cancer Stage IV.

Filter by:
  • Completed  
  • Page 1

NCT ID: NCT03755440 Completed - EBV Clinical Trials

PD-1 Antibody in EBV Positive Metastatic Gastric Cancer Patients.

Start date: December 1, 2018
Phase: Phase 2
Study type: Interventional

EBV positive tumor accounts for 8-9% of all gastric cancer (GC) patients. PD-1 antibody has been proved as third line therapy for PD-L1 positive gastric cancer. Previous studies showed that EBV(+) tumors exhibit high response to PD-1 antibody. In this phase II study, we will investigate the efficacy and safety of PD-1 antibody in EBV positive metastatic GC patients.

NCT ID: NCT03618758 Completed - Clinical trials for Peritoneal Carcinomatosis

Intraperitoneal Paclitaxel Plus Systemic mFOLFOX6

IPLUS
Start date: December 24, 2018
Phase: Phase 1/Phase 2
Study type: Interventional

Treatment for stage 4 gastric cancer with peritoneal carcinomatosis has been unchanged for decades. The median survival for stage 4 gastric cancer is 9-14 months with systemic chemotherapy. Intraperitoneal chemotherapy in combination with systemic chemotherapy is under many clinical trials mainly in Japan, and are showing promising results. This is Korea's first clinical trial on Intraperitoneal Paclitaxel with Systemic mFOLFOX6 chemotherapy.

NCT ID: NCT03159585 Completed - Solid Tumor Clinical Trials

To Evaluate the Efficacy of NY-ESO-1-specific T Cell Receptor Affinity Enhancing Specific T Cell in Solid Tumors

Start date: April 14, 2017
Phase: Phase 1
Study type: Interventional

The main purpose of this trial is to investigate the safety and tolerability of TAEST16001(TCR Affinity Enhancing Specific T cell Therapy)in the multi-line treatment failed advanced solid tumors except non small cell lung cancer,including liver cancer,gastric cancer,esophageal cancer,bone and soft tissue tumors,breast cancer, bladder carcinoma,prostate carcinoma,thyroid cancer, ovarian cancer and so on. The patients must meet the two criteria: human leukocyte antigens (HLA)-A*0201+ and NY-ESO-1 positive cells≥25% by immunohistochemistry.